Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding [Seeking Alpha]
Ovid Therapeutics Inc. (OVID)
Last ovid therapeutics inc. earnings: 3/11 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.ovidrx.com
Company Research
Source: Seeking Alpha
Recent Phase 1 data show OV329 lacks the eye toxicity seen with vigabatrin, supporting its differentiated safety profile. Management secured $60M PIPE financing, extending the cash runway into 2029, but a $385.7M modeled funding gap implies 11% annual dilution over six years. I maintain a speculative buy rating on OVID, citing OV329's potential, recent positive developments, and a fair value per share of $2.16. Fabian Montano/iStock via Getty Images Overview Months following my last evaluation , Ovid Therapeutics' ( OVID lead partnered drug, soticlestat, flunked a Phase 3 trial. Its stock hasn't yet recovered from that event. But my focus (even back then) was on Ovid's GABA-AT inhibitor, OV329. This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions.
Show less
Read more
Impact Snapshot
Event Time:
OVID
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OVID alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OVID alerts
High impacting Ovid Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
OVID
News
- Ovid Therapeutics (OVID) had its price target raised by Wedbush from $5.00 to $7.00. They now have an "outperform" rating on the stock.MarketBeat
- Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Here's Why Ovid Therapeutics Stock Popped Higher Today [Yahoo! Finance]Yahoo! Finance
- Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
OVID
Earnings
- 3/18/26 - Beat
OVID
Sec Filings
- 3/18/26 - Form S-8
- 3/18/26 - Form 10-K
- 3/18/26 - Form 8-K
- OVID's page on the SEC website